Johnson & Johnson $JNJ Shares Purchased by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 173,647 shares of the company’s stock after purchasing an additional 5,497 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Johnson & Johnson were worth $32,198,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of JNJ. SOA Wealth Advisors LLC. grew its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after purchasing an additional 53 shares in the last quarter. Ethos Financial Group LLC grew its stake in shares of Johnson & Johnson by 0.6% during the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after acquiring an additional 53 shares in the last quarter. Heritage Oak Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 3.5% during the third quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock worth $304,000 after acquiring an additional 55 shares during the last quarter. Investor s Fiduciary Advisor Network LLC lifted its stake in shares of Johnson & Johnson by 0.8% in the third quarter. Investor s Fiduciary Advisor Network LLC now owns 6,905 shares of the company’s stock worth $1,280,000 after acquiring an additional 55 shares in the last quarter. Finally, Lifestyle Asset Management Inc. boosted its holdings in Johnson & Johnson by 3.4% in the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after purchasing an additional 56 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on JNJ shares. Daiwa Capital Markets lifted their price objective on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a report on Thursday, January 29th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Wolfe Research increased their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Raymond James Financial boosted their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Finally, Barclays upped their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $233.73.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $233.11 on Wednesday. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $235.20. The stock has a market capitalization of $561.62 billion, a P/E ratio of 21.10, a P/E/G ratio of 2.24 and a beta of 0.35. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average price is $211.74 and its two-hundred day moving average price is $192.73.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. During the same period last year, the company earned $2.04 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s payout ratio is currently 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Multiple analyst upgrades and higher price targets — Morgan Stanley upgraded JNJ to Overweight and raised its PT to $262, RBC lifted its PT to $255 with an Outperform rating, BofA nudged its PT to $227, and other outlets report a PT raised to $265; these moves signal stronger analyst conviction on JNJ’s earnings and margin outlook. Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 RBC Raises Price Target on Johnson & Johnson to $255 BofA lifts PT on Johnson & Johnson (JNJ) to $227 from $221 – here’s why Johnson & Johnson (NYSE:JNJ) Price Target Raised to $265.00
• Positive Sentiment: MedTech/product progress: J&J MedTech announced updates to its Varipulse product and a new ultrasound catheter, which can expand procedure use and revenue potential in vascular/interventional markets. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter
• Positive Sentiment: Commercial rollout: J&J launched the first daily-disposable multifocal toric contact lens for astigmatic presbyopic patients in the U.K. and Ireland (ACUVUE®), supporting the consumer/vision revenue stream. Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia
• Positive Sentiment: Investor access: Management will present at the TD Cowen Health Care Conference on March 3 — a chance to hear updated guidance, pipeline milestones and margin drivers directly from management. Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Context piece: A Forbes analysis reviews JNJ’s ~52% run over the past nine months, attributing gains to improved earnings, product wins and legal progress — useful background but not an immediate catalyst. What’s Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.